SAN DIEGO, CA -- (MARKET WIRE) -- June 21, 2006 -- Tulip BioMed, Inc. (PINKSHEETS: TPBD),
formerly known as Cell Bio-Systems, a developer of medical devices and
patented technologies for the living tissue markets,
including plastic, cosmetic, and orthopedic surgeries, today announced it
has received initial feedback on its new Fat Transfer Kit, which contains
its recently FDA-approved disposable surgical instruments.

The first commercial procedures using this new technology were performed by
Dr. Robert Alexander of Seattle, Washington. Dr. Alexander is
Board-certified in cosmetic surgery, recognized as one of the top plastic
surgeons in the United States, and is a pioneer in fat transfer procedures,
having performed more than a thousand of these procedures. As a member of
Tulip BioMed's Board of Scientific Advisors, Dr. Alexander was one of the
first physicians to receive promotional micro-cannula kits for use in live
surgery using fat transfer procedures after the instruments received FDA
clearance in May.

Dr. Alexander reports positive results. "The disposable cannulas are very
easy to use, and the super-luer is the best," said Alexander. "With the
hydrophilic coating on the inside and outside of the instruments, they
become more slippery when wet; after two to three passes, resistance
effectively disappears. And the cellular sizes are very even, with minimal
or no matrix."

Plastic surgeons look for minimal resistance with a surgical cannula
because less resistance allows the instrument to more easily slip through
human tissue, causing less trauma to the cells and potentially supporting a
reduced recovery time period.

"We are ecstatic, but not surprised, about the feedback from Dr.
Alexander," said CEO Marc Pilkington. "We have done a lot of work and
preparation to make sure that these kinds of results would occur using our
disposable cannulas. This is just the first of many testimonials we are
anticipating."

According to Darin Andersen, president and COO of Tulip BioMed, after
completing the first production pieces earmarked for promotional and sample
kits, Tulip BioMed now has 48,000 pieces in various stages of final
production, from final assembly through sterilization. Another 48,000
pieces are in the initial stages of manufacturing and a third batch of
48,000 pieces is entering the approval process.

"This feedback underscores the real need for this new technology," said
Andersen. "We are working hard to fill the product pipeline to meet the
expected demand for this product."

About Tulip BioMed, Inc.

Tulip BioMed, Inc. (PINKSHEETS: TPBD), formerly known as Cell Bio-Systems,
Inc., is a Nevada corporation with operations based in San Diego,
California. Founded in 2004, Tulip BioMed, Inc. is a medical device,
biotechnology company that manufactures and distributes patented
technologies for the plastic and cosmetic surgery, biopsy, orthopedic
surgery, stem cell therapy and other living tissue markets. Tulip BioMed,
Inc. is the exclusive licensee of patented syringe connection devices that
use the worldwide-recognized Tulip brand name. Tulip BioMed, Inc.
manufactures, markets, and distributes medical devices, adapted with these
and other patented technologies, to physicians, clinics, military, health
organizations, hospitals and other distribution outlets. For more
information, go to: www.tulipbiomed.com. Products are available for sale
at www.tulipdisposable.com.

Safe Harbor: This press release contains certain forward-looking
information about Tulip BioMed, Inc., formerly Cell Bio-Systems, Inc.
("Cell Bio-Systems"), which is intended to be covered by the safe harbor
for "forward-looking statements" provided by the Private Securities
Litigation Reform Act of 1995. Forward-looking statements are statements
that are not historical facts. Words such as "expect(s)," "feel(s),"
"believe(s)," "will," "may," "anticipate(s)," and similar expressions are
intended to identify forward-looking statements. These statements include,
but are not limited to, financial projections and estimates and their
underlying assumptions; statements regarding plans, objectives and
expectations with respect to future operations, products and services; and
statements regarding future performance. Such statements are subject to
certain risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Tulip BioMed, Inc., that could cause actual
results to differ materially from those expressed in, or implied or
projected by, the forward-looking information and statements. These risks
and uncertainties include: our lack of operating revenue and earnings
history, our need for additional capital to pursue our business strategy.
We are a non-reporting company and as such do not make periodic filings
with the Securities and Exchange Commission. We trade on the Pink Sheets
and there can be no assurances that a liquid market will develop in our
securities. Readers are cautioned not to place undue reliance on these
forward-looking statements. Tulip BioMed, Inc. does not undertake any
obligation to republish revised forward-looking statements to reflect
events or circumstances after the date hereof or to reflect the occurrence
of unanticipated events.